<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882685</url>
  </required_header>
  <id_info>
    <org_study_id>HUS214/2016</org_study_id>
    <nct_id>NCT02882685</nct_id>
  </id_info>
  <brief_title>Comparison of Mini Gastric Bypass and Roux-en-Y Gastric Bypass</brief_title>
  <acronym>RYSA</acronym>
  <official_title>Comparison of Two Operative Techniques - Mini Gastric Bypass and Roux-en-Y Gastric Bypass in the Treatment of Severe Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares Roux-en-Y gastric bypass with single anastomosis gastric bypass in a
      randomized prospective setting. This study also adresses the issue of bile reflux after MGB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Roux-en-Y gastric bypass (RYGB) and single anastomosis gastric bypass (SAGB or mini gastric
      bypass, MGB) have both shown excellent weight-loss and effect on comorbidities such as type 2
      diabetes.

      In this study eligible patients are randomized for either of the operations. Effects on
      glucose homeostasis as well as weight-loss and the effect on comorbidities are recorded
      during the follow-up. Interim analysies will be done for the first 60 patients (30 per group)
      after the first month and at 6 months. In the first interim analysis perioperative outcomes
      and continuos glucose monitoring will be analyzed. In the second interim analysis nutritional
      deficiencies and early complications as well as early weight-loss data will be analyzed.

      At 12 months, all outcomes for all patients will be analyzed. Follow-up continues at
      24months, 4years, 7years and 10 years after the surgery and follow-up data will be analyzed
      accordingly.

      Also, MGB has been feared to cause bile reflux. The first 30 MGB patients will undergo a
      gastroscopy and a hepatobiliary scintigraphy for bile reflux detection at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight-loss</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>During the follow-up the weight (kg) is measured for all participants at operation, 1 month, 3 months, 6 months, 12 months, 2 years, 4 years, 7 years and ten years after the operation. Weight-loss is calculated as excess weight-loss compared to the preoperative weight 2 months before the operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>2 months before the operation glucose homeostasis status is studied (oral glucose tolerance test). Oral glucose tolerance tests will be repeated at 6months and 12 months. Continuos glucose monitoring will be done before the operation at operation and 6 months after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile reflux after Mini Gastric Bypass</measure>
    <time_frame>6 months</time_frame>
    <description>All patients undergo a gastroscopy prior to inclusion. Patients with Barrets esophagus or LA B-C esophagitis are excluded. The first 30 patients, who are randomized to Mini Gastric Bypass will undergo a gastroscopy and a hepatobiliary scintigraphy 6 months after the operation. At hepatobiliary scintigraphy the amount of bile reflux is calculated as the amount of tracer found in the gastric pouch or esophagus in relation to total amount of tracer in the liver.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roux-en-Y gastric bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single anastomosis gastric bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-y gastric bypass</intervention_name>
    <arm_group_label>RYGB</arm_group_label>
    <other_name>RYGB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single anastomosis gastric bypass</intervention_name>
    <arm_group_label>SAGB</arm_group_label>
    <other_name>SAGB</other_name>
    <other_name>Mini-gastric bypass</other_name>
    <other_name>MGB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI&gt;35

        Exclusion Criteria:

          -  Pregnancy

          -  Previous bariatric surgery

          -  Anemia

          -  esophagitis (LA B-D)

          -  esophageal intestinal metaplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuure T Saarinen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tuure T Saarinen, MD</last_name>
    <phone>+358503631709</phone>
    <email>tuure.saarinen@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne T Juuti, MD PhD</last_name>
    <phone>+358 9 4711</phone>
    <email>anne.juuti@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuure T Saarinen, MD</last_name>
      <phone>+358503631709</phone>
      <email>tuure.saarinen@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Anne T Juuti, MD PhD</last_name>
      <phone>+358 9 4711</phone>
      <email>anne.juuti@hus.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanna Meriläinen, M.D.</last_name>
      <email>sanna.merilainen@ppshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Vesa Koivukangas, M.D.</last_name>
      <email>vesa.koivukangas@ppshp.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Sanna Meriläinen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vesa Koivukangas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Tuure Saarinen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Roux-en-Y gastric bypass</keyword>
  <keyword>Mini-gastric bypass</keyword>
  <keyword>Single anastomosis gastric bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

